United States Últimas notícias

Emera (NYSE:EMA) reported robust financial results for the first quarter of 2026, signaling a strong start toward its annual growth targets.

Johnson Outdoors (NASDAQ:JOUT) delivered a sharp financial turnaround in its fiscal second quarter, signaling a robust recovery in the outdoor recreation market.

Gravity (NASDAQ:GRVY) reported a powerful start to 2026, with first-quarter financial results reflecting a major resurgence for its flagship Ragnarok franchise.

Docebo (NASDAQ:DCBO) reported solid financial results for the first quarter of 2026, underscored by a successful transition toward a more diversified customer base and record-setting cash flow efficiency.

Cango (NYSE:CANG) provided its monthly operational update for April 2026, revealing a strategic shift toward margin preservation and fleet modernization over aggressive scale.

Century Casinos (NASDAQ:CNTY) delivered a record-breaking performance for the opening quarter of 2026, signaling that its recent capital investments and geographic diversification are beginning to yield higher operational efficiency.

ChipMOS Technologies (NASDAQ:IMOS) reported unaudited consolidated revenue for April 2026 that highlights the continued strength of the global semiconductor recovery, particularly within the artificial intelligence (AI) vertical.

Interface (NASDAQ:TILE), the global leader in sustainable flooring, opened 2026 with significant momentum, reporting first-quarter financial results that exceeded expectations across all key metrics.

Robo.ai (NASDAQ:AIIO) announced a transformative $100 million all-stock agreement to acquire 100% of Neurovia AI, a move intended to accelerate the company’s transition from digital software to the backbone of physical artificial intelligence.

United Microelectronics (NYSE:UMC) reported strong top-line momentum for the start of the second quarter, with April 2026 net sales climbing 10.8% year-over-year.

BioArctic announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental Biologics License Application (sBLA) for Leqembi Iqlik (lecanemab-irmb).

Autoliv (NYSE:ALV) unveiled a significant restructuring of its European operations, announcing a phased withdrawal from manufacturing in Türkiye as part of a broader effort to optimize its regional production capacity.